CN Stock MarketDetailed Quotes

600276 Jiangsu Hengrui Pharmaceuticals

Watchlist
  • 46.25
  • -0.29-0.62%
Market Closed Dec 20 15:00 CST
295.03BMarket Cap54.16P/E (TTM)

Jiangsu Hengrui Pharmaceuticals Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Jiangsu Hengrui Pharmaceuticals Q3 2024 Earnings Date

Currency：CNYOct 25, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
6.73B
6.59B
-145.67M
Miss Est.
+15.21%
+12.72%
-2.16%
EPS
0.23
0.19
-0.04
Miss Est.
+19.05%
--
-16.00%
Analyst Rating
Strong Buy

Dec 22, 2024

Jiangsu Hengrui Pharmaceuticals Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 2 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: CNY

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 6.572B--
--2024/Q4-- / 7.088B--
Oct 25, 20242024/Q36.589B / 6.734B--
Aug 22, 20242024/Q27.603B / 6.648B--
Apr 18, 20242024/Q15.998B / 6.071B--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 6.572B--
--2024/Q4-- / 7.088B--
Oct 25, 20242024/Q36.589B / 6.734B--
Aug 22, 20242024/Q27.603B / 6.648B--
Apr 18, 20242024/Q15.998B / 6.071B--

Unlock Free Earnings Estimates

Jiangsu Hengrui Pharmaceuticals Earnings Reports

  • Hengrui Pharmaceutical Report for the Third Quarter of 2024

    Oct 25 00:00

  • Jiangsu Hengrui Pharmaceuticals 2024 Semi-Annual Report

    Aug 22 00:00

  • Summary of Jiangsu Hengrui Pharmaceuticals' 2024 interim report

    Aug 22 00:00

  • Summary of Hengrui Pharmaceutical\'s 2023 Annual Report

    Apr 18 00:00

    • Read more

    Top CN Stock Gainers
    Symbol Price % Chg
    Zhejiang Lanyu Digital Technology
    301585
    73.00 +204.80%
    BBK Test Systems
    301598
    83.98 +118.36%
    MEIZHIGAO
    834765
    29.18 +29.98%
    Youkeshu Technology
    300209
    5.75 +20.04%
    Hangzhou Raycloud Technology Co.,Ltd
    688365
    13.90 +20.03%

    See the daily top gainer.

    Analysis

    Analyst Rating

    Updated: Dec 22, 2024

    Strong Buy

    • Strong Buy

      92.31%

    • Buy

      5.13%

    • Hold

      2.56%

    • Underperform

      0.00%

    • Sell

      0.00%

    Price Target

    No Data